Fixed-duration combinations for first-line CLL treatment—what do the long-term trial results show?

During the 17th International Conference on Malignant Lymphomas (ICML), the Lymphoma Hub spoke with Paolo Ghia, Vita-Salute San Raffaele, Milan, IT. We asked, What do the long-term trial results show for fixed-duration combinations in first-line chronic lymphocytic lymphoma (CLL) treatment.

Ghia discusses RESONATE (NCT01578707) and CAPTIVATE (NCT02910583), two long term follow-up studies highlighted at ICML evaluating ibrutinib with venetoclax or ofatumumab as a fixed therapy in patients with CLL. Key conclusions discussed are the incidence of adverse events, progression-free survival and overall survival, time to next treatment, and impact of minimum residual disease. He describes these data as favorable for patients with CLL and explains that minimum residual disease status impacts response rates. Further study is required to investigate follow-up treatment options if patients are seen to relapse after 6 years.